Yisheng’s biological product for pancreatic cancer gets Orphan Drug Designation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Yisheng Biopharma Co., Ltd., said the FDA has granted orphan drug designation for its lead immuno-oncology candidate, YS-ON-001, for pancreatic cancer.

To date, FDA has granted YS-ON-001 two ODDs for the treatment of pancreatic cancer and hepatocellular carcinoma. YS-ON-001 is a clinical-stage immuno-oncology biologic product with unique immunomodulating mechanism and broad spectrum of anti-tumor activity.

YS-ON-001 is a clinical stage biological product based on our proprietary immunomodulating cell technology developed in-house at Yisheng Biopharma. It is a multi-component complex with broad immunomodulating properties, such as promoting Th1-biased immunity, inducing the activation and proliferation of dendritic cell, B and natural killer cells, promoting macrophage M1 polarization and downregulating regulatory T cells.

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login